Evidence map›Paper›PMID 41281653›Full record

ArticleMaterials today. Bio2025

A dual-enzyme-like nanozyme adjuvant alleviates tumor hypoxia to enhance photothermally ferroptosis-immune synergistic tumor therapy.

Peng Chang, Dehong Chen, Xiaoyu Yang, Kuoye Tian, Ying Liu, Ke Li, Dan Chen, Wei Wang, Qi Pan, Yun Zeng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026
    Review
  6. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peng ChangSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Dehong ChenSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Xiaoyu YangSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Kuoye TianSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Ying LiuSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Ke LiXi'an Key Laboratory for Prevention and Treatment of Common Aging Diseases, Translational and Research Centre for Prevention and Therapy of Chronic Disease, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, PR China.
Dan ChenSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Wei WangDepartment of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, PR China.
Qi PanDepartment of Radiology and Nuclear Medicine, Xuanwu Hospital Capital Medical University, Beijing, 100053, PR China.
Yun ZengSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Yonghua ZhanSchool of Life Science and Technology, Xidian University and Engineering Research Center of Molecular and Neuro Imaging, Ministry of Education, Xi'an, 710126, PR China.
Wenhua ZhanDepartment of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, 750004, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune adjuvants play a critical role in cancer vaccines and emerging therapies. However, conventional adjuvants may fail to effectively stimulate cytotoxic T lymphocyte (CTL)-mediated immune responses. Nanozyme-based adjuvants, particularly manganese-based nanozymes, demonstrate significant potential by integrating enzymatic activity with immune modulation. Herein, we developed a dual-enzyme-like nanozyme adjuvant (Mn

Indexed as

cGAS-STING pathwayFerroptosisImmunogenic cell deathMelatoninNanozyme adjuvant

Identifiers

PMID41281653
PMCPMC12637074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.